Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Evidence regarding the effectiveness of COVID-19 vaccine in patients with impaired immunity is limited. Initial observations suggest a lower humoral response in these patients. We evaluated the relative effectiveness of the mRNA BNT162b2 vaccine in patients with hematological neoplasms compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittelman, Moshe, Magen, Ori, Barda, Noam, Dagan, Noa, Oster, Howard S., Leader, Avi, Balicer, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Plenary Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526123/
https://www.ncbi.nlm.nih.gov/pubmed/34662390
http://dx.doi.org/10.1182/blood.2021013768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526123/
https://www.ncbi.nlm.nih.gov/pubmed/34662390
http://dx.doi.org/10.1182/blood.2021013768

Ejemplares similares